1. Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration 
Julio Delgado, Gabriela Ghita, Tycho Baumann, Rodrigo Santacruz, Ivan Dlouhy, Marta Aymerich, Maria Rozman, Natalia Creus, Arturo Pereira, Emili Montserrat 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 14, Issue 1, Pages (February 2014)
DOI: /j.clml
Copyright © 2014 Elsevier Inc. Terms and Conditions

2. Figure 1
Overall Survival According to Treatment Group in (A) The Whole Cohort; (B) Patients With Binet Stage A Disease; (C) Patients With Binet Stage B Disease; and (D) Patients With Binet Stage C Disease at Frontline Therapy
Abbreviations: PA = purine analogues; PA+R = PA plus rituximab.
Clinical Lymphoma, Myeloma and Leukemia  , 73-79DOI: ( /j.clml )
Copyright © 2014 Elsevier Inc. Terms and Conditions

3. Figure 2
Overall Survival for Patients Receiving Chemoimmunotherapy According to the Time of Administration. Front-Line (n = 55) vs. ≥ 1 Line (n = 59)
Clinical Lymphoma, Myeloma and Leukemia  , 73-79DOI: ( /j.clml )
Copyright © 2014 Elsevier Inc. Terms and Conditions